Cost-Effectiveness of Systemic Therapies for Metastatic Pancreatic Cancer

Abstract

The most cost-effective treatment for metastatic pancreatic cancer depends on the societal wtp threshold. If the societal wtp threshold were to be relatively high or if drug costs were to be substantially reduced, folfirinox might be cost-effective.